Cargando…

The Subjective Experience of Using Medications: What We Know and the Paths Forward

Medications can cause bodily changes, where the associated benefits and risks are carefully assessed based on the changes experienced in the phenomenal body. For this reason, the phenomenology of Merleau-Ponty is an important theoretical framework for the study of experience related to the daily use...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Almeida Nascimento, Yone, Ramalho-de-Oliveira, Djenane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006003/ https://www.ncbi.nlm.nih.gov/pubmed/33801298 http://dx.doi.org/10.3390/pharmacy9010050

Ejemplares similares

Decision-Making Process in Comprehensive Medication Management Services: From the Understanding to the Development of a Theoretical Model
por: Oliveira, Isabela Viana, et al.
Publicado: (2020)

The Lived Experience of Patients Utilizing Second-Generation Direct-Acting Antiviral for Treatment of Chronic Hepatitis C Virus Infection: A Phenomenological Analysis
por: Nascimento, Yone de Almeida, et al.
Publicado: (2022)

Commentary: Is this a case in which we know what we don't know what we don't know?
por: Nantsios, Alex, et al.
Publicado: (2021)

Commentary: When we don't know what we don't know
por: Paone, Gaetano
Publicado: (2020)

Pregnant adolescents living with HIV: what we know, what we need to know, where we need to go
por: Callahan, Tegan, et al.
Publicado: (2017)

COVID-19 in Children: What We Know and What We Don’t Know?
por: Jat, Kana Ram
Publicado: (2021)

What we know and what we don't know about cancer risks associated with radiation doses from radiological imaging
por: Brenner, D J
Publicado: (2014)

Adolescent pregnancy, nutrition, and health outcomes in low‐ and middle‐income countries: what we know and what we don't know
por: Johnson, W, et al.
Publicado: (2015)

Sodium and brain injury: do we know what we are doing?
por: Zygun, David A
Publicado: (2009)

Understanding the meaning of medications for patients: The medication experience
por: Shoemaker, Sarah J., et al.
Publicado: (2007)

Tight glycemic control: what do we really know, and what should we expect?
por: Nasraway, Stanley A, et al.
Publicado: (2010)

Ocular surface inflammation in dry eye disease: What we know and what we do not
por: Vazirani, Jayesh
Publicado: (2018)

Maintenance of physical activity: Do we know what we are talking about?
por: Kahlert, Daniela
Publicado: (2015)

Deliberate use of placebos in clinical practice: what we really know
por: Harris, Cory S, et al.
Publicado: (2012)

Colonization and infection of the respiratory tract: What do we know?
por: Robinson, Joan
Publicado: (2004)

Ectopic Calcification: What Do We Know and What Is the Way Forward?
por: Snijders, Birgitta M. G., et al.
Publicado: (2023)

Experimental subjects do not know what we think they know
por: Field, Jared M., et al.
Publicado: (2020)

Breast cancer risk perception: what do we know and understand?
por: Hopwood, Penelope
Publicado: (2000)

Curriculum reform: Why? What? How? and how will we know it works?
por: Reis, Shmuel
Publicado: (2018)

Coronavirus and ophthalmology: What do we know and way forward
por: Khanna, Rohit C
Publicado: (2020)

Drug interactions among older adults followed up in a comprehensive medication management service at Primary Care
por: dos Santos, Tayane Oliveira, et al.
Publicado: (2019)

The Path Forward for COVID-19 Diagnostics
por: Usherwood, Thomas, et al.
Publicado: (2020)

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?
por: Politis, Marios
Publicado: (2010)

Chikungunya and diabetes, what do we know?
por: de Almeida Barreto, Francisca Kalline, et al.
Publicado: (2018)

Reducing Racial Inequities in Health: Using What We Already Know to Take Action
por: Williams, David R., et al.
Publicado: (2019)

Cardiac amyloidosis and surgery: What do we know about rare diseases?
por: Mestres, Carlos A., et al.
Publicado: (2021)

COVID‐19 infection in CVID patients: What we know so far
por: Weifenbach, Niels, et al.
Publicado: (2021)

A Personal Prospective on Testosterone Therapy in Women—What We Know in 2022
por: Donovitz, Gary S.
Publicado: (2022)

COVID-19 Imaging: What We Know Now and What Remains Unknown
por: Kanne, Jeffrey P., et al.
Publicado: (2021)

Trastuzumab-related cardiotoxicity: what do we know in 2020?
por: Liu, Jia, et al.
Publicado: (2020)

Alzheimer's disease therapeutic research: the path forward
por: Aisen, Paul S
Publicado: (2009)

‘Psychodermatology’: The present standing and a path forward
por: Mostaghimi, L., et al.
Publicado: (2022)

Ten myths and twenty years: What we know and what we still do not know about work addiction: Commentary on: Ten myths about work addiction (Griffiths et al., 2018)
por: Kun, Bernadette
Publicado: (2018)

The Role of the Microbiome in Autism: All That We Know about All That We Don’t Know
por: David, Maude M.
Publicado: (2021)

Forward We Go!
por: Nezhat, Farr R., et al.
Publicado: (2023)

What we learned from STEP that we didn't already know from SPRINT
por: Modesti, Pietro Amedeo
Publicado: (2021)

The postictal state — What do we know?
por: Pottkämper, Julia C. M., et al.
Publicado: (2020)

What we know about 2019-nCoV in Iran in the early stage?
por: Dodangeh, Milad, et al.
Publicado: (2020)

Diet, nutrition, and cancer risk: what do we know and what is the way forward?
por: Key, Timothy J, et al.
Publicado: (2020)

The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2tsr60vn6n4lob8nnh674cib6b